Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Payables: 2021-2024

Historic Payables for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to $2.9 million.

  • Amylyx Pharmaceuticals' Payables rose 259.05% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.4 million, marking a year-over-year decrease of 67.21%. This contributed to the annual value of $2.9 million for FY2024, which is 86.68% down from last year.
  • According to the latest figures from FY2024, Amylyx Pharmaceuticals' Payables is $2.9 million, which was down 86.68% from $22.1 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Payables registered a high of $22.1 million during FY2023, and its lowest value of $2.9 million during FY2024.
  • Its 3-year average for Payables is $10.4 million, with a median of $6.3 million in 2022.
  • In the last 5 years, Amylyx Pharmaceuticals' Payables soared by 252.58% in 2023 and then plummeted by 86.68% in 2024.
  • Amylyx Pharmaceuticals' Payables (Yearly) stood at $4.4 million in 2021, then spiked by 43.12% to $6.3 million in 2022, then soared by 252.58% to $22.1 million in 2023, then tumbled by 86.68% to $2.9 million in 2024.